Anzeige
Mehr »
Mittwoch, 01.10.2025 - Börsentäglich über 12.000 News
Breaking News: Golden Cross entdeckt hochgradiges Gold - Ein neues Fosterville im Milliarden-Dollar-Gürtel von Victoria?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JAZX | ISIN: SE0006371126 | Ticker-Symbol: 7V3
Frankfurt
30.09.25 | 08:04
0,207 Euro
+0,49 % +0,001
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CANTARGIA AB Chart 1 Jahr
5-Tage-Chart
CANTARGIA AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,2110,26130.09.

Aktuelle News zur CANTARGIA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
00:26Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC216LUND, SE / ACCESS Newswire / September 30, 2025 / Cantargia (STO:CANTA)High IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while this...
► Artikel lesen
11.09.Cantargia Closes the Acquisition of CAN10 by Otsuka253LUND, SE / ACCESS Newswire / September 11, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that Cantargia and its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) have closed Otsuka's...
► Artikel lesen
CANTARGIA Aktie jetzt für 0€ handeln
29.08.Cantargia im Q2 2025: Otsuka-Deal bringt 33 Mio. USD Sofortzahlung bei durchwachsenen klinischen Ergebnissen5
29.08.Cantargia Q2 2025 slides: Otsuka deal brings $33M upfront amid mixed clinical results2
27.08.Cantargia Granted Important US Patent for Nadunolimab192LUND, SE / ACCESS Newswire / August 27, 2025 / Cantargia AB (Publ), Nasdaq Stockholm:CANTA, (Cantargia) today announced that the United States Patent and Trademark Office (USPTO) has granted the patent...
► Artikel lesen
21.08.Cantargia: Aktie gibt trotz 630-Mio.-Dollar-Deal mit Otsuka nach5
21.08.Cantargia Publishes Half-Year Report 2025292LUND, SE / ACCESS Newswire / August 21, 2025 / Cantargia AB (publ) [Nasdaq Stockholm:CANTA] (Cantargia) today issued the interim report for January to June 2025."I started my tenure as interim CEO with...
► Artikel lesen
18.08.Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer335Dr Steineger's appointment will be effective from September 1.She brings extensive experience as a biotech executive, with a proven track record spanning financial analysis, venture capital, and business...
► Artikel lesen
12.08.Invitation to the Presentation of Cantargia's H1 2025 Report245LUND, SE / ACCESS Newswire / August 12, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first six months of 2025 on Thursday, August...
► Artikel lesen
17.07.Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer393LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA)Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolerated...
► Artikel lesen
16.07.Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer327LUND, SE / ACCESS Newswire / July 16, 2025 / Cantargia (STO:CANTA)Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival...
► Artikel lesen
15.07.Otsuka to acquire Cantargia's CAN10 for autoimmune diseases4
15.07.Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical422Cantargia receives an upfront cash payment of USD 33 million.Cantargia is eligible to receive up to USD 580 million in development, regulatory and commercial milestone payments plus earn-out payments...
► Artikel lesen
17.06.Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans328LUND, SE / ACCESS Newswire / June 17, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced that it has entered into a loan agreement of SEK 50 million...
► Artikel lesen
17.06.Cantargia Q1 2025 slides: CAN10 advances amid funding challenges3
11.06.Cantargia's Nadunolimab Aantibody Awarded US FDA Fast Track Designation808Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further development...
► Artikel lesen
19.05.Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation261IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques.IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1,...
► Artikel lesen
15.05.Bulletin from the Annual General Meeting in Cantargia AB329LUND, SWEDEN / ACCESS Newswire / May 15, 2025 / The Annual General Meeting of Cantargia (STO:CANTA) on May 15, 2025 resolved in accordance with the following:That no dividend would be paid.To discharge...
► Artikel lesen
13.05.Cantargia Publishes Interim Report for the First Quarter of 2025470LUND, SE / ACCESS Newswire / May 13, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced its interim report for the first quarter of 2025."The first...
► Artikel lesen
12.05.Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2297LUND, SE / ACCESS Newswire / May 12, 2025 / Cantargia (STO:CANTA)Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort.Model...
► Artikel lesen
Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1